Biotech's Next Gold Rush Isn't Where You Think It Is

Eli Lilly is playing a double game. Their injectable candidate, lepodisiran, uses siRNA technology (think of it as a molecular shredder for the genetic blueprints that produce Lp(a)). In phase 2 trials, a single dose reduced Lp(a) by a jaw-dropping 94%, with effects lasting over a year. Meanwhile, Lilly is also developing muvalaplin, an oral pill that cut Lp(a) by up to 85.8% in phase 2. A pill you swallow versus an injection you get once or twice a year: Lilly wants to own both lanes.

Amgen brings olpasiran, another siRNA approach given as a shot every 12 weeks. Phase 2 showed Lp(a) reductions exceeding 90% for most doses through 48 weeks, with a clean safety profile.

And Silence Therapeutics has zerlasiran, yet another siRNA candidate that achieved over 80% average reduction across 36 weeks. They're currently looking for a partner to fund phase 3 trials.

The $200 Billion Question

So how does this compare to GLP-1 drugs? Honestly, it's not a fair fight yet. The GLP-1 obesity market is projected to hit around $10 billion in 2026, with J.P. Morgan forecasting the broader incretin market could reach $200 billion globally by 2030.

Lp(a) inhibitors, by contrast, have exactly $0 in revenue. No approved products. No commercial infrastructure. The comparison to GLP-1s is less about where things stand today and more about trajectory. GLP-1 drugs were once niche diabetes treatments before someone realized they could reshape the entire obesity market. Analysts see Lp(a) following a similar arc: a scientifically validated target with a massive patient population, just waiting for the clinical proof to unlock it.

That proof lives or dies with the HORIZON trial.

Summer 2026: The Moment of Truth

If pelacarsen's HORIZON data show that lowering Lp(a) by 70-80% actually reduces heart attacks and strokes, the floodgates open. Regulatory filings could come as early as the second half of 2026. Every other company in the space would ride the wave, because the fundamental question (does lowering this molecule save lives?) would finally be answered.

If HORIZON disappoints, the calculus changes dramatically. It wouldn't necessarily kill the category; the trial only tests secondary prevention (people who've already had a cardiac event). Primary prevention, treating healthy people with high Lp(a) before anything bad happens, represents the truly massive market. But a failed first trial would cool enthusiasm fast and push timelines out by years.

BioCentury has flagged Lp(a) catalysts as major cardiovascular catalysts in 2026. The confidence is high, but confidence isn't data.

Why This Time Feels Different

Cardiovascular drug development has a long history of promising targets that flopped in large trials. Raising HDL ("good cholesterol") was supposed to be the next big thing for a decade before multiple expensive failures buried the hypothesis. So why should anyone believe Lp(a) is different?

Two reasons stand out. First, the genetic evidence is unusually strong. Mendelian randomization studies, which use natural genetic variation as a kind of real-world experiment, consistently link high Lp(a) to cardiovascular events. Second, the drugs actually work at lowering the target. We're not talking about modest 20-30% reductions. These candidates are erasing 80-94% of circulating Lp(a). If the biology is right, the pharmacology is more than up to the task.

The "diabolical" molecule might finally have met its match. We'll know by summer.

The Bottom Line

Lp(a) inhibitors sit at a rare inflection point: a validated genetic target, a population of billions worldwide, multiple advanced candidates, and a definitive trial about to read out. Calling it the next GLP-1 is premature. But calling it the most exciting cardiovascular opportunity in a generation? That's getting harder to argue against.

The gold rush has started. The question is whether there's actually gold in the hills, or just really convincing pyrite. HORIZON's data will tell us which.

Why Pharma Still Can't Crack Menopause (and It's Not for Lack of Trying)

About 6,000 women enter menopause daily in the U.S., and the market opportunity tops $120 billion. So why does the pharmaceutical industry keep stumbling on drugs for it? The answer involves ghost studies, broken trial designs, and a system that still treats half the population's health as a niche.